BCM
FHTX icon

Bridgeway Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Bridgeway Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Buy
89,600
+15,000
+20% +$66.6K 0.01% 883
2026
Q1 		$357K Hold
74,600
– – 0.01% 892
2025
Q4 		$403K Hold
74,600
– – 0.01% 866
2025
Q3 		$365K Buy
74,600
+10,500
+16% +$55.7K 0.01% 871
2025
Q2 		$301K Buy
64,100
+25,000
+64% +$104K 0.01% 862
2025
Q1 		$143K Buy
39,100
+5,600
+17% +$25.5K ﹤0.01% 985
2024
Q4 		$158K Sell
33,500
-25,000
-43% -$182K ﹤0.01% 1051
2024
Q3 		$545K Buy
58,500
+1,000
+2% +$7.24K 0.01% 842
2024
Q2 		$331K Buy
+57,500
New +$342K 0.01% 952

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bridgeway Capital Management's FHTX Position: Q2 2026 in Review

Bridgeway Capital Management increased its Foghorn Therapeutics (FHTX) stake by 20% in Q2 2026, buying an estimated $66.6K and bringing the position to 89,600 shares worth $437K. The position accounts for 0.01% of the portfolio, ranked #883.

Bridgeway Capital Management first reported a position in FHTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $545K in Q3 2024. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Bridgeway Capital Management held 89,600 shares of Foghorn Therapeutics worth $437K as of Q2 2026.
  • Bridgeway Capital Management bought 15,000 Foghorn Therapeutics shares in Q2 2026, an estimated $66.6K.
  • Foghorn Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #883 holding.
  • Bridgeway Capital Management first reported a position in Foghorn Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Bridgeway Capital Management's Foghorn Therapeutics position peaked at $545K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.